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post-transplant was 69% (95%CI 64%, 74%). For pts with malignant
disease, disease-free survival at 1 year was 50% (95% CI 43%, 56%).
Based on Cox proportional hazards models, the success of transplan-
tation was predominantly dependent on pt characteristics: pts with
non-malign disease, CMV seronegativity, and males had improved
outcomes. CD34 dose was associated with improved neutrophil and
platelet engraftment. In multivariate analyses, TNC (95% pts had
2.5  107/kg), HLA match (4/6 vs 5 or 6/6 types at transplant) or
HR HLA match (8/10 vs 8/10) were not signiﬁcantly associated
with any of the end points. In conclusion, HLA 4-6 of 6 matched
CBUs with 2.5  107/kg TNC provide excellent transplant results
for pediatric patients with malign (OS 57% [95% CI 50%, 63%] at 1
year) and non-malign (OS 71% [95% CI 61%, 80%] at 1 year)
diseases.
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UNRELATED CORD BLOOD TRANSPLANTATION AFTER MYELOABLA-
TIVE CONDITIONING IN ADULT PATIENTS WITH ACUTE LEUKEMIA
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Although allogeneic stem cell transplantation from a human
leukocyte antigen (HLA)-identical related donor offers a potential
cure for patients with acute leukemia, a suitably matched related
donor is unavailable for approximately two-thirds of patients. Re-
cently, umbilical cord blood from unrelated donors has been used
as an alternative stem cell source for adult patients with hemato-
logical malignancies. Here, we updated the results of unrelated
cord blood transplantation (CBT) after myeloablative conditioning
for 69 adult patients with acute leukemia. Between August 1998
and April 2005, 69 adult patients with acute leukemia were treated
with unrelated CBT at The Institute of Medical Science, Univer-
sity of Tokyo. Diagnoses at transplantation included de novo AML
(n  38), ALL (n  16), and MDS-related secondary AML (n 
15). All patients received four fractionated 12 Gy total body irra-
diation and chemotherapy as myeloablative conditioning. 66 pa-
tients received standard cyclosporine (CyA) and methotrexate, and
3 patients received CyA only as a graft-versus-host disease
(GVHD) prophylaxis. Among the patients the median age was 41
years (range, 18-55 years), the median weight was 55 kg (range,
36-76 kg) and the median number of cryopreserved nucleated cells
was 2.50  107/kg (range, 1.16-5.29  107/kg). 65 patients had
myeloid reconstitution and the median time to more than 0.5 
109/L absolute neutrophil count was 21 days. A self-sustained
platelet count more than 50 109/L was achieved in 59 patients at
a median time of 39 days. Acute GVHD above grade II occurred in
39 of 65 evaluable patients and chronic GVHD occurred in 37 of
47 evaluable patients. Among 37 chronic GVHD patients, 12
patients were extensive type. 46 patients are alive and free of
disease at between 126 and 2562 days after transplantation. With a
median follow-up of 1259 days, the probability of disease-free
survival at 3 years was 69.0%. These results suggest that adult acute
leukemia patients without suitable related or unrelated bone mar-
row donors should be considered as candidates for CBT.
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Failure to recognize the appropriate HLA class I ligands on the
target cell triggers the inhibitory killer Ig-like receptors (KIR) to
initiate cytotoxicity and may contribute to graft-vs.-leukemia
(GVL) effect. Past studies have shown GVL advantage of the
absence (incompatibility) of recipient HLA ligands to donor KIR
genes in select patients (pts) undergoing myeloablative transplan-
tation. Here we examine if similar advantage is seen in non-
myeloablative transplant (NMT). The KIR-HLA ligand combina-
tions studied were: KIR2DL1-Cw4 (Asn77Lys80); KIR2DL2/3-
Cw3 (Ser77Asn80); KIR3DL1-Bw4; and KIR3DL2-A3/A11. The
KIR typing was performed by rSSOP and HLA-C allele typing by
SBT. Twenty-two lymphoid malignancy (LM) pts with ALL, HD,
or NHL and 20 myeloid malignancy (MM) pts with AML or MDS
were studied. The median age of LM and MM were both 45 years.
All had relapsed/refractory disease, and/or co-morbidities preclud-
ing ablative transplantation. Peripheral blood hematopoietic stem
cell graft from haploidentical family donors with alemtuzumab (20
mg  5), ﬂudarabine (30 mg/m2  4), and cyclophosphamide (500
mg/m2 4) regimen and mycophenolate cyclosporine in vitro
alemtuzumab prophylaxis was used. Most donors were 3-4/6 HLA
matched (75% in MM and 82% in LM). Each pair was evaluated
for the donor KIR genotype and lack of corresponding class I
ligands. Kaplan-Meier curves were compared using log-rank test.
The impact of NK cell cytotoxicity was assessed by relapse related
mortality (RRM). RRM in MM group was appreciably lower if
there was KIR/HLA-C ligand incompatibility (P .059). One year
probability of RRM is 14% (95% conﬁdence: 0-37%) in the in-
compatible group compared to 71% (95% conﬁdence: 28-89%) in
the compatible group (P  .059). In addition, RRM is lower
though not reaching statistical signiﬁcance (P  .070) if the in-
compatibility existed for 2 or 3 KIR/HLA ligand combinations
(17%; 95% conﬁdence: 0-42%) in comparison to no or 1 combi-
nation (66%; 95% conﬁdence: 25-85%). There were no differ-
ences in RRM in LM group (P  .784 for HLA-C; P  .16 for
Bw4; 0.752 for A3/11) with regard to KIR/HLA ligand matching.
KIR-HLA ligand incompatibility did not increase the probability
of grade 2-4 AGVHD in the MM group (P .247 for HLA-C; P
.467 for Bw4; 0.357 for A3/11). These results suggest that KIR/
HLA ligand incompatibility contributes to GVL effect without an
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One of the major barriers to the broader use of haploidentical
stem cell transplantation (SCT) is the high mortality from viral
infections due to poor immune reconstitution. One approach to
safely overcome this problem is to infuse donor T-cells from which
alloreactive lymphocytes have been selectively depleted, but the
immunological beneﬁt of this approach is unknown. We have
previously demonstrated that an anti-CD25 immunotoxin effec-
tively depletes alloreactive donor lymphocytes from co-cultures of
donor mononuclear cells and host lymphoblastoid cell lines with
preservation of in vitro anti-viral responses. In the current study we
have compared immune reconstitution after allodepleted donor
T-cells were infused at 2 dose levels into recipients of haploiden-
tical SCT. Patients were scheduled to receive 3 doses of allode-
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